{"id":965237,"date":"2026-05-20T09:27:03","date_gmt":"2026-05-20T13:27:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/"},"modified":"2026-05-20T09:27:03","modified_gmt":"2026-05-20T13:27:03","slug":"ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/","title":{"rendered":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity"},"content":{"rendered":"
\n

\n Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies<\/em>\n <\/p>\n

\n Segment also discusses evolving treatment landscape, immunologically \u201ccold\u201d tumors and the future potential of off-the-shelf cell therapy approaches<\/em>\n <\/p>\n

\n Access the segment <\/em>
\n
\n here<\/em>
\n <\/a>\n <\/p>\n

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics<\/u><\/a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences<\/a> at Yale University School of Medicine and a member of Ernexa\u2019s Board of Directors.
\u202f\u00a0
As part of the segment, Dr. Ratner discusses ovarian cancer, one of the most difficult malignancies to treat, and highlights the significant challenges patients continue to face throughout diagnosis and treatment. The discussion explores limitations of current therapeutic approaches and the persistent unmet need for more effective and durable treatment options.<\/p>\n

Dr. Ratner also discusses the evolving ovarian cancer treatment landscape and shares her perspective on Ernexa\u2019s differentiated biological approach to addressing immunologically \u201ccold\u201d tumors. The segment highlights Ernexa\u2019s lead product candidate, ERNA-101, and recently announced preclinical data demonstrating complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade.<\/p>\n

The discussion also highlights the potential advantages of Ernexa\u2019s engineered allogeneic induced mesenchymal stem cell (iMSC) platform, including the opportunity to develop scalable, off-the-shelf cell therapies designed to improve accessibility and overcome manufacturing challenges associated with traditional autologous approaches.<\/p>\n

The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here<\/a>. For more information about ERNA-101 and the Company\u2019s development plans, visit www.ernexatx.com<\/a><\/p>\n

\n About Ernexa Therapeutics<\/strong>\n <\/p>\n

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa\u2019s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa\u2019s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.<\/p>\n

ERNA-101 is the company\u2019s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company\u2019s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.<\/p>\n

For more information, visit www.ernexatx.com<\/u><\/a>.<\/p>\n

\n Media Contact<\/strong>
\n
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com<\/u><\/a><\/p>\n

\n Investor Contact<\/strong>
\n
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically \u201ccold\u201d tumors and the future potential of off-the-shelf cell therapy approaches Access the segment here CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa\u2019s Board of Directors.\u202f\u00a0As part of the segment, Dr. Ratner discusses ovarian cancer, one of the … <\/p>\n

Continue reading “Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965237","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nErnexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically \u201ccold\u201d tumors and the future potential of off-the-shelf cell therapy approaches Access the segment here CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa\u2019s Board of Directors.\u202f\u00a0As part of the segment, Dr. Ratner discusses ovarian cancer, one of the … Continue reading "Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T13:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity\",\"datePublished\":\"2026-05-20T13:27:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/\"},\"wordCount\":436,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/\",\"name\":\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=\",\"datePublished\":\"2026-05-20T13:27:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - Market Newsdesk","og_description":"Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically \u201ccold\u201d tumors and the future potential of off-the-shelf cell therapy approaches Access the segment here CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa\u2019s Board of Directors.\u202f\u00a0As part of the segment, Dr. Ratner discusses ovarian cancer, one of the … Continue reading \"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-20T13:27:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity","datePublished":"2026-05-20T13:27:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/"},"wordCount":436,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/","name":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=","datePublished":"2026-05-20T13:27:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzU3NSM3NjEyMzQ1IzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-featuring-dr-elena-ratner-highlighting-ovarian-cancer-landscape-and-erna-101-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965237"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965237\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}